Minerva Surgical (UTRS) Stock Price, News & Analysis

Company Overview

Minerva Surgical, Inc. is a medical technology company that develops and commercializes devices for the treatment of benign gynecologic conditions. The company’s flagship product, the Minerva System, is designed to perform next‐generation endometrial ablation—a minimally invasive procedure used to treat heavy menstrual bleeding. By combining real‐time visualization, precise treatment control and an integrated fluid management system, the Minerva System aims to deliver a consistent, single‐procedure solution for women seeking alternatives to traditional surgical interventions.

The Minerva System features a proprietary treatment device, single‐use accessories and an intuitive console interface. Its core technology allows physicians to visualize the uterine cavity during the procedure, automate the energy delivery process and maintain continuous fluid balance to enhance patient safety. This platform is intended for use in outpatient and ambulatory care settings, potentially reducing treatment times and improving patient recovery experiences compared with more invasive surgical approaches.

Headquartered in Redwood City, California, Minerva Surgical secured U.S. Food and Drug Administration clearance for its system in 2015 and commenced commercial launch shortly thereafter. Since that time, the company has focused on expanding its sales and training initiatives across the United States, partnering with gynecologists, ambulatory surgery centers and hospital systems to drive adoption. Minerva Surgical also pursues strategic collaborations to explore future applications of its thermal ablation technology.

Founded by Daniel P. Hale, who serves as chief executive officer, Minerva Surgical is led by a management team with combined expertise in medical device development, commercialization and women’s health. The board and executive leadership continue to guide the company’s efforts to broaden access to minimally invasive gynecologic treatments and to develop next‐generation solutions for physicians and patients alike.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 278 shs
• Market Capitalization: $1 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

UTRS Stock Analysis - Frequently Asked Questions

How were Minerva Surgical's earnings last quarter?

Minerva Surgical, Inc. (NASDAQ:UTRS) posted its earnings results on Wednesday, December, 1st. The company reported ($23.00) earnings per share for the quarter, missing analysts' consensus estimates of ($8.80) by $14.20. The business earned $12.51 million during the quarter, compared to analyst estimates of $12.23 million.

When did Minerva Surgical's stock split?

Minerva Surgical shares reverse split on the morning of Monday, October 2nd 2023.The 1-20 reverse split was announced on Monday, October 2nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 2nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Minerva Surgical IPO?

Minerva Surgical (UTRS) raised $100 million in an initial public offering on Friday, October 22nd 2021. The company issued 6,250,000 shares at $15.00-$17.00 per share.

How do I buy shares of Minerva Surgical?

Shares of UTRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Minerva Surgical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Minerva Surgical investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 12/01/2021
• Today: 9/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:UTRS
• CIK: 1452965
• Web: www.minervasurgical.com
• Phone: 855-646-7874
• Fax: N/A
• Employees: 160
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $51.69 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 8,879,000
• Free Float: 8,124,000
• Market Cap: $1 thousand
• Optionable: Not Optionable
• Beta: 3.53